Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28084648 | 0.78 | ALDH1A1 (0.61) | PTGS2 | |
| SCHEMBL14296483 | 0.78 | INPPL1 (0.32) | — | |
| SCHEMBL11547843 | 0.77 | HTT (0.58) | PTGS2PTGS1ENPP2SMN1; SMN2 | |
| SCHEMBL18038657 | 0.75 | INPPL1 (0.31) | — | |
| SCHEMBL2376239 | 0.75 | ENPP2 (0.72) | PTGS2ENPP2 | |
| SCHEMBL11657087 | 0.75 | HTR6 (0.56) | SMN1; SMN2PKM | |
| SCHEMBL11986371 | 0.75 | PKM (0.70) | PTGS2PTGS1PKM | |
| SCHEMBL280156 | 0.75 | PKM (0.70) | PTGS2PTGS1PKM | |
| SCHEMBL1487482 | 0.74 | ENPP2 (0.46) | PTGS2PTGS1ENPP2PKM | |
| SCHEMBL28670163 | 0.73 | MMP2 (0.51) | PTGS2PTGS1ENPP2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140212382-A1 | PURINE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140212382-A1 | PURINE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | PNP, MTAP, NT5C3B | PTGS2 2820/4885PTGS1 3342/4885ENPP2 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.